PDS Biotechnology
PDSB
44 hedge funds and large institutions have $6.07M invested in PDS Biotechnology in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 11 closing their positions.
213% more capital inflows, than outflows
Capital inflows: $3M | Capital outflows: $958K
4.14% more ownership
Funds ownership: 11.95% → 16.09% (+4.1%)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
6% less funds holding
Funds holding: 47 → 44 (-3)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$2.56M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$95.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$46.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.7K |
| 5 |
Bank of New York Mellon
New York
|
+$36.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$390K |
| 2 |
Inspirion Wealth Advisors
Libertyville,
Illinois
|
-$148K |
| 3 |
Renaissance Technologies
New York
|
-$89.4K |
| 4 |
Squarepoint
New York
|
-$89.4K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$61K |
PDSB Hedge Fund Activity: Q4 2025 in Review
44 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2025, worth a combined $6.07M — down 8.6% from $6.64M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PDSB and 10 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 11 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.56M. The largest seller was Citadel Advisors, exiting entirely with an estimated $390K sold.
- 44 institutional investors held PDS Biotechnology (PDSB) as of Q4 2025, down from 47 in Q3 2025.
- Funds reported $6.07M of PDS Biotechnology stock for Q4 2025, down 8.6% quarter-over-quarter.
- 10 funds opened new PDS Biotechnology positions in Q4 2025 and 11 closed out, a net change of -1 holder.
- The largest PDS Biotechnology buyer in Q4 2025 was Armistice Capital, an estimated $2.56M added.
- The largest PDS Biotechnology seller in Q4 2025 was Citadel Advisors, an estimated $390K sold.
Based on aggregated 13F filings for Q4 2025.